Ceftazidime

Ceftazidime
Clinical data
Pronunciation	/sɛfˈtæzɪdiːm/; sef-TAZ-i-deem
Trade names	Fortaz, Tazicef, others
AHFS/Drugs.com	Monograph
MedlinePlus	a686007
License data	EU EMA: by INN; US DailyMed: Ceftazidime;
Pregnancy; category	AU: B1;
Routes of; administration	Intravenous, intramuscular, inhalation
Drug class	Third-generation cephalosporin
ATC code	J01DD02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	91% (IM)
Metabolism	negligible
Elimination half-life	1.6–2 hours
Excretion	90–96% kidney
Identifiers
	IUPAC name (6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetamido)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylate;
CAS Number	72558-82-8 ;
PubChem CID	5481173;
DrugBank	DB00438 ;
ChemSpider	4587145 ;
UNII	DZR1ENT301;
ChEBI	CHEBI:3508 ;
ChEMBL	ChEMBL44354 ;
CompTox Dashboard (EPA)	DTXSID5022770 ;
ECHA InfoCard	100.069.720
Chemical and physical data
Formula	C22H22N6O7S2
Molar mass	546.57 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(=NOC(C(=O)O)(C)C)c3nc(sc3)N)C[n+]4ccccc4)C([O-])=O;
	InChI InChI=1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13-/t14-,18-/m1/s1 ; Key:ORFOPKXBNMVMKC-DWVKKRMSSA-N ;
	(what is this?) (verify)

Ceftazidime, sold under the brand name Fortaz among others, is a third-generation cephalosporin antibiotic useful for the treatment of a number of bacterial infections.^[1]^[4] Specifically it is used for joint infections, meningitis, pneumonia, sepsis, urinary tract infections, malignant otitis externa, Pseudomonas aeruginosa infection, and vibrio infection.^[1] It is given by injection into a vein, muscle, or eye.^[1]^[5]

Common side effects include nausea, allergic reactions, and pain at the site of injection.^[1] Other side effects may include Clostridioides difficile diarrhea.^[1] It is not recommended in people who have had previous anaphylaxis to a penicillin.^[1] Its use is relatively safe during pregnancy and breastfeeding.^[6] It is in the third-generation cephalosporin family of medications and works by interfering with the bacteria's cell wall.^[1]

Ceftazidime was patented in 1978 and came into commercial use in 1984.^[7] It is on the World Health Organization's List of Essential Medicines.^[8] Ceftazidime is available as a generic medication.^[1]

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ "Ceftazidime". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.
^ "Fortaz- ceftazidime injection, powder, for solution". DailyMed. U.S. National Library of Medicine. 28 July 2017. Archived from the original on 28 December 2021. Retrieved 12 June 2022.
^ "Tazicef- ceftazidime injection, powder, for solution". DailyMed. U.S. National Library of Medicine. 24 March 2022. Archived from the original on 28 December 2021. Retrieved 12 June 2022.
^ Katzung B (2019). Basic & Clinical Pharmacology (14th ed.). McGraw Hill. p. 803. ISBN 978-1-259-64115-2.
^ Kamjoo S. "Intravitreal Injections". EyeWiki. American Academy of Ophthalmology. Archived from the original on 5 March 2021. Retrieved 12 January 2020.
^ Hamilton R (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 87. ISBN 9781284057560.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 495. ISBN 9783527607495. Archived from the original on 2016-12-20.
^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.